1. Home
  2. PCSA vs POLA Comparison

PCSA vs POLA Comparison

Compare PCSA & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$1.84

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Logo Polar Power Inc.

POLA

Polar Power Inc.

HOLD

Current Price

$1.31

Market Cap

6.0M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
POLA
Founded
2011
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
6.0M
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
PCSA
POLA
Price
$1.84
$1.31
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
★ $25.00
N/A
AVG Volume (30 Days)
21.0K
★ 66.7K
Earning Date
05-11-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$5,000.00
★ $24,801,141.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 3.14
52 Week Low
$0.11
$1.23
52 Week High
$8.88
$5.70

Technical Indicators

Market Signals
Indicator
PCSA
POLA
Relative Strength Index (RSI) 41.18 40.87
Support Level $1.80 N/A
Resistance Level $2.33 $1.93
Average True Range (ATR) 0.14 0.07
MACD -0.00 0.01
Stochastic Oscillator 5.48 38.89

Price Performance

Historical Comparison
PCSA
POLA

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

About POLA Polar Power Inc.

Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Other Asia Pacific, Europe and Middle East, United Kingdom, and South Africa.

Share on Social Networks: